Radiomics Analysis of PET and CT Components of PET/CT Imaging Integrated with Clinical Parameters: Application to Prognosis for Nasopharyngeal Carcinoma.
Clinical parameter
Nasopharyngeal carcinoma
Prognosis
Radiomics
[18F]FDG PET/CT
Journal
Molecular imaging and biology
ISSN: 1860-2002
Titre abrégé: Mol Imaging Biol
Pays: United States
ID NLM: 101125610
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
24
1
2019
medline:
30
5
2020
entrez:
24
1
2019
Statut:
ppublish
Résumé
To investigate the prognostic performance of radiomics features, as extracted from positron emission tomography (PET) and X-ray computed tomography (CT) components of baseline 2-deoxy-2-[ One hundred twenty-eight NPC patients (85 vs. 43 for training vs. validation), containing a subset of 86 patients with local-regional advanced stage, were enrolled. All patients underwent pretreatment PET/CT scans (mean follow-up time 24 ± 14 months). Three thousand two hundred seventy-six radiomics features extracted from PET or CT components and 13 clinical parameters were used to predict progression-free survival (PFS). Univariate analysis with Benjamini-Hochberg false discovery rate (FDR) correction was first used to screen significant features, and redundant features with Spearman's correlation > 0.8 were further eliminated. Then, seven multivariate models involving PET features and/or CT features and/or clinical parameters (denoted as clinical, PET, CT, clinical + PET, clinical + CT, PET + CT and clinical + PET + CT) were constructed by forward stepwise multivariate Cox regression. Model performance was evaluated by concordance index (C-index). Sixty patients encountered events (28 recurrences, 17 metastases, and 15 deaths). Six clinical parameters, 3 PET features, and 14 CT features in training cohort and 4 clinical parameters, 10 PET features, and 4 CT features in subset of local-regional advanced stage were significantly associated with PFS. Combining PET and/or CT features with clinical parameters showed equal or higher prognostic performance than models with PET or CT or clinical parameters alone (C-index 0.71-0.76 vs. 0.67-0.73 and 0.62-0.75 vs. 0.54-0.75 for training and validation cohorts, respectively), while the prognostic performance was significantly improved in local-regional advanced cohort (C-index 0.67-0.84 vs. 0.64-0.77, p value 0.001-0.059). Radiomics features extracted from the PET and CT components of baseline PET/CT images provide complementary prognostic information and improved outcome prediction for NPC patients compared with use of clinical parameters alone.
Identifiants
pubmed: 30671740
doi: 10.1007/s11307-018-01304-3
pii: 10.1007/s11307-018-01304-3
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
954-964Références
Sci Rep. 2015 Jun 05;5:11044
pubmed: 26251068
Eur Radiol. 2017 Mar;27(3):1012-1020
pubmed: 27380902
Eur Radiol. 2018 Aug;28(8):3245-3254
pubmed: 29520429
AJNR Am J Neuroradiol. 2016 Sep;37(9):1706-12
pubmed: 27151750
Radiother Oncol. 2015 Sep;116(3):462-6
pubmed: 26163091
Eur J Cancer. 2013 Jul;49(10):2356-64
pubmed: 23541571
Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1649-1660
pubmed: 29623375
Eur J Nucl Med Mol Imaging. 2017 Apr;44(4):567-580
pubmed: 27999896
IEEE Trans Med Imaging. 2009 Mar;28(3):374-83
pubmed: 19244009
Acta Oncol. 2017 Nov;56(11):1544-1553
pubmed: 28885084
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):618-25
pubmed: 19683403
Radiother Oncol. 2012 Feb;102(2):239-45
pubmed: 22098794
Comput Med Imaging Graph. 2002 Jan-Feb;26(1):33-42
pubmed: 11734372
Clin Cancer Res. 2013 Jul 1;19(13):3591-9
pubmed: 23659970
Eur Radiol. 2018 Jan;28(1):428-436
pubmed: 28770406
J Nucl Med. 2011 Mar;52(3):369-78
pubmed: 21321270
Mol Imaging Biol. 2016 Oct;18(5):788-95
pubmed: 26920355
Clin Cancer Res. 2016 Dec 1;22(23):5765-5771
pubmed: 27803067
Laryngoscope. 2017 Jan;127(1):E22-E28
pubmed: 27435352
Acta Oncol. 2015;54(9):1423-9
pubmed: 26264429
Clin Oncol (R Coll Radiol). 2013 Nov;25(11):639-46
pubmed: 23910226
Oral Oncol. 2017 Aug;71:150-155
pubmed: 28688683
Cancer. 2013 Mar 1;119(5):963-70
pubmed: 23065693
Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):921-928
pubmed: 28807534
Acta Oncol. 2013 Oct;52(7):1391-7
pubmed: 24047337
AJR Am J Roentgenol. 2012 Jul;199(1):169-74
pubmed: 22733909
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):365-375
pubmed: 29046927
Expert Rev Precis Med Drug Dev. 2016;1(2):207-226
pubmed: 28042608
Nucl Med Commun. 2011 Nov;32(11):989-96
pubmed: 21862944
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):151-165
pubmed: 27271051
J Appl Clin Med Phys. 2017 Nov;18(6):32-48
pubmed: 28891217
Med Phys. 2017 Jul;44(7):3686-3694
pubmed: 28422299
Anticancer Drugs. 2010 Jun;21(5):471-7
pubmed: 20124988
Eur J Cancer. 2010 Jul;46(11):1967-78
pubmed: 20451372
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1090-1097
pubmed: 29246722
Phys Med Biol. 2015 Jul 21;60(14):5471-96
pubmed: 26119045
Sci Rep. 2015 Aug 05;5:11075
pubmed: 26242464
Radiology. 2016 Sep;280(3):880-9
pubmed: 27326665
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
J Nucl Med. 2013 Oct;54(10):1703-9
pubmed: 24042030
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
J Nucl Med. 2017 Mar;58(3):365-366
pubmed: 27811126
Radiother Oncol. 2015 Mar;114(3):345-50
pubmed: 25746350
Oncol Lett. 2017 Oct;14(4):5004-5012
pubmed: 29085513
Transl Cancer Res. 2016 Aug;5(4):371-382
pubmed: 30627523
Clin Cancer Res. 2017 Aug 1;23(15):4259-4269
pubmed: 28280088
Phys Med Biol. 2016 Jan 7;61(1):227-42
pubmed: 26639024
J Nucl Med. 2012 Jan;53(1):21-8
pubmed: 22213820
J Nucl Med. 2016 Mar;57(3):342-7
pubmed: 26541775
J Natl Cancer Inst. 2010 Aug 4;102(15):1188-98
pubmed: 20634482
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1477-85
pubmed: 26896298
Clin Cancer Res. 2015 Jan 15;21(2):249-57
pubmed: 25421725
Mol Imaging Biol. 2016 Dec;18(6):935-945
pubmed: 27324369
J Clin Oncol. 2015 Oct 10;33(29):3356-64
pubmed: 26351355
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):207-217
pubmed: 28944403
J Nucl Med. 2018 Aug;59(8):1321-1328
pubmed: 29301932